Who Paid My Doc
Anamaria Munteanu
Molecular Genetic Pathology Los Angeles, CA Medical Doctor
NPI 1689161275 CMS profile 7233608
10833 Le Conte Ave, Los Angeles, CA 90095
General payments
$401
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Anamaria Munteanu of Los Angeles, CA is reported in the CMS Open Payments database as having received $401 across 7 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $96 | 1 | |
| 2024 | General | $247 | 2 | |
| 2019 | General | $57 | 4 |
Beside peers
- Anamaria Munteanu
- Molecular Genetic Pathology median
- Middle half of Molecular Genetic Pathology
- National median
In program year 2025, general payments to Anamaria Munteanu were reported at $96. Among 27 Molecular Genetic Pathology profiles paid that year, the median was $225 and the middle half received between $91 and $3,596.
Show as a table
| Year | Anamaria Munteanu | Molecular Genetic Pathology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $57 | $131 | $38–$1,524 | $163 |
| 2020 | $0 | — | — | $114 |
| 2021 | $0 | $900 | $25–$1,899 | $132 |
| 2022 | $0 | $136 | $28–$4,738 | $149 |
| 2023 | $0 | $139 | $48–$3,150 | $160 |
| 2024 | $247 | $1,077 | $71–$2,833 | $164 |
| 2025 | $96 | $225 | $91–$3,596 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 27 billing codesPaid by Medicare
$99,425
Medicare patients
119
Services billed
2,675
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 72% | |
| Arthritis | 63% | |
| Depression | 36% | |
| Diabetes | 34% | |
| Ischemic heart disease | 34% | |
| Chronic kidney disease | 32% | |
| Osteoporosis | 25% | |
| Heart failure | 22% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
7 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Molecular Genetic Pathology in California
Girish Putcha
Molecular Genetic Pathology · Stanford, CA
Jeffry Simko
Molecular Genetic Pathology · San Francisco, CA
Beatrice Knudsen
Molecular Genetic Pathology · Los Angeles, CA
Jennifer Hummel
Molecular Genetic Pathology · Aliso Viejo, CA
Patricia Aoun
Molecular Genetic Pathology · Duarte, CA
Danica Wiredja
Molecular Genetic Pathology · Stanford, CA
Related records
Molecular Genetic Pathology in California
Practitioners in the same specialty and state, ranked by reported value.
All Molecular Genetic Pathology
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.